Form 4 Filing for ALNYLAM PHARMACEUTICALS, INC.

This filing details a Form 4 for ALNYLAM PHARMACEUTICALS, INC., reporting transactions by Benjamin Cravatt, who is a director. On June 1, 2026, Cravatt acquired 4,393 shares through a stock option grant. The option has an exercise price of $295.63 and vests in three equal parts on the first, second, and third anniversaries of the grant date, with full vesting by June 1, 2027. The option expires on June 1, 2036. Following this transaction, Cravatt directly owns 4,393 shares. The filing was signed on June 3, 2026, by Brett Budzinski as attorney-in-fact for Benjamin Cravatt.